Health ❯ Healthcare ❯ Clinical Trials ❯ Phase III Trials

SERENA-6 Trial

FDA Approves Camizestrant for ESR1‑Mutated Advanced Breast Cancer

The decision lets doctors switch an aromatase inhibitor to the oral SERD camizestrant after a blood test finds an ESR1 resistance mutation, with confirmatory trials required.

13 ARTICLES

5mo ago

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy